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ABSTRACT
Autophagy is a highly coordinated process that is controlled at several levels including transcriptional
regulation. Here, we identify the transcription factor NFE2L2/NRF2 (nuclear factor, erythroid 2 like 2) as a
regulator of autophagy gene expression and its relevance in a mouse model of Alzheimer disease (AD)
that reproduces impaired APP (amyloid b precursor protein) and human (Hs)MAPT/TAU processing,
clearance and aggregation. We screened the chromatin immunoprecipitation database ENCODE for 2
proteins, MAFK and BACH1, that bind the NFE2L2-regulated enhancer antioxidant response element (ARE).
Using a script generated from the JASPAR’s consensus ARE sequence, we identiﬁed 27 putative AREs in 16
autophagy-related genes. Twelve of these sequences were validated as NFE2L2 regulated AREs in 9
autophagy genes by additional ChIP assays and quantitative RT-PCR on human and mouse cells after
NFE2L2 activation with sulforaphane. Mouse embryo ﬁbroblasts of nfe2l2-knockout mice exhibited
reduced expression of autophagy genes, which was rescued by an NFE2L2 expressing lentivirus, and
impaired autophagy ﬂux when exposed to hydrogen peroxide. NFE2L2-deﬁcient mice co-expressing
HsAPPV717I and HsMAPTP301L, exhibited more intracellular aggregates of these proteins and reduced
neuronal levels of SQSTM1/p62, CALCOCO2/NDP52, ULK1, ATG5 and GABARAPL1. Also, colocalization of
HsAPPV717I and HsMAPTP301L with the NFE2L2-regulated autophagy marker SQSTM1/p62 was reduced in
the absence of NFE2L2. In AD patients, neurons expressing high levels of APP or MAPT also expressed
SQSTM1/p62 and nuclear NFE2L2, suggesting their attempt to degrade intraneuronal aggregates through
autophagy. This study shows that NFE2L2 modulates autophagy gene expression and suggests a new
strategy to combat proteinopathies.
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Introduction
The homeostatic control of protein synthesis, folding, trafﬁcking
and degradation, i.e. proteostasis, is critical for biological pro-
cesses, and its alterations lead to pathological outcome, including
neurodegenerative diseases.1 The 2 main mechanisms that con-
trol protein degradation are the 20S and 26S proteasome and
autophagy in its 3 primary modalities, microautophagy, chaper-
one-mediated autophagy and macroautophagy.2 These processes
ensure timely degradation of misfolded, oxidized or altered pro-
teins that otherwise develop proteinopathy. In particular, macro-
autophagy, usually termed autophagy, participates in the
degradation of long-lived proteins that, if improperly cleared,
aggregate and cause cellular damage.
The autophagy process requires the coordinated participation
of a set of structural proteins that participate in the formation of
autophagosomes and autolysosomes, as well as cargo-selective
proteins that recognize speciﬁc cargos and direct them to degra-
dation.3 Most studies on the regulation of macroautophagy have
focused on protein-protein interactions based on MTOR-depen-
dent mechanisms. For instance, upon serum-deprivation or inhi-
bition by rapamycin, low MTOR activity allows ULK1 activation
by disruption of the interaction with AMP kinase and results in
increased autophagy.4 Because these regulatory mechanisms are
cell signaling dependent, they probably represent a quick adapta-
tion to cellular needs of a speciﬁc moment. Other reports indi-
cate positive5-8 and negative9,10 transcriptional regulation of
autophagy, which might represent a long-term mechanism of
adaptation. Two documented transcription factors that fulﬁll this
role are the helix-loop-helix transcription factor TFEB and the
forkhead transcription factor FOXO.11,12 Given the complexity
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of the macroautophagy system and the need for a coordinated
interplay between autophagy-regulated and -regulating proteins,
it is hypothesized that the expression of autophagy genes is con-
nected through additional common regulatory transcription fac-
tor(s).
Considering that autophagy is a proteostatic and defensive
mechanism, we sought to determine if this process is regulated
by NFE2L2/NRF2 (nuclear factor, erythroid 2 like 2). The
transcription factor NFE2L2 is considered a master regulator
of cellular homeostasis, as it controls the expression of numer-
ous cytoprotective genes.13,14 These genes share a common cis-
acting element in their promoters, named the antioxidant
response element (ARE), and the list of cytoprotective genes
that contain this enhancer is continuously growing to include
those involved in biotransformation, antioxidant defense, and
metabolic reprogramming. Regarding autophagy, the cargo
recognition protein SQSTM1/p62 contains the motif KIR that
interacts with KEAP1 leading to its transport into the phago-
phore (the autophagosome precursor) and relieving NFE2L2
from inhibition.15,16 In connection with this ﬁnding, SQSTM1
contains one ARE and is therefore upregulated by NFE2L2,
creating a feed-forward cycle.17 The cargo recognition protein
CALCOCO2/NDP52 also appears to be regulated by NFE2L2,
leading to the clearance of toxic proteins such as phosphory-
lated HsMAPT (p-MAPT) in a mouse model of AD, while 3
different ARE sequences were identiﬁed in its promoter
region.18
Impaired proteostasis is a crucial hallmark of neurodegener-
ative diseases.19-21 Protein pathology in AD is related to the
altered processing of APP, which leads to intracellular accumu-
lation and extracellular deposition of amyloid-b (Ab) peptides,
as well as aggregation of p-MAPT into intracellular neuroﬁbril-
lary tangles.22 Both APP and HsMAPT are degraded, at least in
part, through autophagy and several reports suggest that this
process is altered in AD. For instance, dystrophic neurites of
AD patients contain more autophagosomes,23 increased levels
of MTOR signaling components and lysosomal hydrolases.24
In this study, we sought to determine if genes that partici-
pate in autophagy are regulated by NFE2L2. Our results sup-
port our hypothesis that NFE2L2 participates in the regulation
of autophagy gene expression and suggest a new therapeutic
strategy for proteinopathies based on the activation of this tran-
scription factor.
Results
Identiﬁcation of putative AREs in autophagy genes
To deﬁne comprehensively the role of NFE2L2 in the transcrip-
tional regulation of autophagy, we searched the Encyclopedia of
DNA Elements at UCSC (ENCODE)25 of the human genome
(Feb. 2009) for autophagy genes with putative AREs. This data-
base contains the experimental data from chromatin immuno-
precipitation (ChIP) studies of several transcription factors.
Although NFE2L2 is not included, we analyzed 2 other ARE
binding factors, MAFK and BACH1, for which information is
available. We found evidence of MAFK or BACH1 binding in
many genes involved directly or indirectly in autophagy. Then,
we developed a Python-based bioinformatics analysis script, to
compare the consensus human ARE from the JASPAR data-
base26 with putative AREs in the promoter regions of these
genes (for details see Material and methods and Tables S1 and
S2). We detected 25 putative new AREs (relative score over
80%) in these 16 autophagy genes, besides the internal controls
that our algorithm retrieved as the bona ﬁde ARE-genes in
NQO1 and HMOX1 (Table 1). Some of these genes, such as
SQSTM117 or CALCOCO2 18 were reported to be regulated by
NFE2L2, and for SQSTM1 we identiﬁed the previously
described ARE17 plus 3 new sequences. The other autophagy
ARE-genes were identiﬁed here for the ﬁrst time. Moreover,
several putative AREs are conserved in mice (Tables S1–S3).
Validation of putative AREs by ChIP and qRT-PCR
The newly identiﬁed ARE sequences were subsequently vali-
dated by ChIP assays for NFE2L2. Because of the lack of ade-
quate antibodies to immunoprecipitate endogenous NFE2L2
efﬁciently, we used HEK293T cells transfected with an expres-
sion vector for V5-tagged NFE2L2. Moreover, this construct
lacked the KEAP1 regulatory domain (ETGE), facilitating
NFE2L2 stabilization, its translocation to the nucleus and
binding to target genes.27 ChIPs were performed with anti-V5
antibody, and with anti-IgG as negative control. Immunopre-
cipitated DNA was analyzed by quantitative real time PCR
(qRT-PCR) with speciﬁc primers surrounding the putative
AREs (Table S4).
Table 1. Putative Antioxidant Response Elements (AREs) in the promoter regions
of autophagy genes with a relative score higher than 80%. The table also shows
the max score and the localization in the human genome.
GENE
(human)
Localization in
the human genome
Max
score
Relative
score
ARE putative
binding sequence
SQSTM1 chr5:179247562-179247551 19.11 1.0 ATGACTCAGCA (1)
chr5:179246594-179246583 18.97 0.997 GTGACTCAGCA(2)
chr5:179247479-179247490 11.44 0.816 GCGACCTAGCA (3)
chr5:179246116-179246105 13.39 0.863 GTGAGTCAGCG (4)
CALCOCO2 chr17:46906385-46906374 12.65 0.845 ATGAGTAAGCC
chr17:46906430-46906441 12.34 0.838 GTGAGGAAGCA
ULK1 chr12:132381043-132381032 12.62 0.844 ATTAGTCAGCA
ULK2 chr17:19783789-19783800 15.74 0.919 GTGACAGAGCA
ATG2B chr14:96849918-96849929 11.38 0.815 CTGCCTAAGCA
ATG4C chr1:63212369-63212380 13.03 0.854 ATGAAATAGCA
ATG4D chr19:10652326-10652315 14.96 0.9 ATGACAATGCA
chr19:10655902-10655891 10.94 0.804 GTGACTTTGAA
ATG5 chr6:106873861-106873872 11.01 0.806 CTGACCTTGCA
ATG7 chr3:11347170-11347159 15.94 0.924 ATGAGTCAGCA
chr3:11320731-11320720 13.65 0.869 CTGACTCAGCT
chr3:11347216-11347227 11.08 0.807 AGGACTTGGCA
chr3:11320599-11320610 11.07 0.807 ATGATTGAGCT
GABARAPL1 chr12:10364974-10364963 14.58 0.891 GTGACTCAGGA
chr12:10366072-10366083 18.97 0.997 GTGACTCAGCA
ATG9B chr7:150723213-150723224 14.24 0.883 CTGACTCAGCC
ATG10 chr5:81278192-81278181 16.65 0.941 CTGACTCAGCA
ATG16L1 chr2:234134609-234134598 16.53 0.938 ATGATTCAGCA
chr2:234134578-234134589 13.56 0.867 ATGACCTAGCC
WIPI2 chr7:5239766-5239755 16.65 0.941 ATGACTGAGCA
LAMP1 chr13:113951364-113951353 12.06 0.831 GTGACCCGGCC
AMBRA1 chr11:46576251-46576240 11.51 0.818 TTGACTTAGCT
chr11:46572300-46572311 10.84 0.802 ATGACTAATCT
NQO1 chr16:69760919-69760908 18.97 0.997 GTGACTCAGCA
HMOX1 chr22:35768205-35768216 12.3 0.837 ATGCCTCAGCC
chr22:35768021-35768010 18.97 0.997 GTGACTCAGCA
chr22:35768127-35768116 18.97 0.997 GTGACTCAGCA
chr22:35747111-35747100 13.24 0.859 GTTACTCAGCC
Asterisks denote AREs that have been described previously.
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Among the 27 putative AREs analyzed in autophagy genes we
found enrichment of 11 ARE regions in V5-immunoprecipitated
chromatin, indicating that NFE2L2 binds these promoter regions
(Fig. 1A-B). Our study also detected enrichment of 2 positive
controls from the bona ﬁde NFE2L2 targets NQO1 and HMOX1.
No enrichment was detected with speciﬁc primers for ACTB, for
an upstream region of NQO1 that does not contain AREs,28 or
for ATG3, all of which had low scores for putative AREs in the
bioinformatics analysis. Negative control assays were further per-
formed without antibodies or on nontransfected cells (data not
shown). Next, we sought to determine the existence of other
potential AREs in the SQSTM1 promoter aside from the one
already described.17 For this purpose we used speciﬁc primers
surrounding the other potential AREs (Table S4 and Table 1).
We observed that NFE2L2 bound to all these sequences
(Fig. 1B), demonstrating that they constitute additional AREs in
this gene.
We went on to further conﬁrm our observations in
HEK293T cells, treated with the NFE2L2 activator sulforaph-
ane (SFN) (15 mM, 12 h), which has been used previously to
induce autophagy.29-31 Transcript levels of the selected auto-
phagy genes were analyzed by qRT-PCR, demonstrating
increased expression of SQSTM1, CALCOCO2, ULK1, ATG2B,
ATG4D, ATG5, and GABARAPL1 upon SFN treatment
(Fig. 1C). HMOX1 was analyzed and conﬁrmed as a positive
control. We next extended our observations to murine cells by
analyzing hippocampus-derived HT22 cells treated with SFN
(15 mM, 12 h). SFN augmented the expression of all the murine
counterparts of the genes identiﬁed in the human cells
(Fig. 1D). The combined results indicated that the regulation of
expression of autophagy genes is conserved in both species.
We next analyzed the expression of these genes in mouse
embryonic ﬁbroblasts (MEFs) from wild-type (Nfe2l2-WT) or
Nfe2l2-knockout (Nfe2l2-KO) mice by qRT-PCR (Fig. 2A).
Impaired expression of Sqstm1, Calcoco2, Ulk1, Atg2b, Atg4d,
Atg5, Atg7 and Gabarapl1 was observed in Nfe2l2-KO MEFs.
Moreover, reduced expression of Sqstm1, Calcoco2 and Atg7
products was also conﬁrmed at the protein level with available
antibodies (Fig. 2B-C).
To further deﬁne the role of NFE2L2 in the regulation of
these autophagy genes we performed chemical and genetic
manipulations of this transcription factor. In response to SFN
nfe2l2-KO MEFs exhibited a reduced induction of these genes
compared to Nfe2l2-WT MEFs (Fig. 2D). In addition, rescue
experiments in nfe2l2-KO MEFs employing NFE2L2-DEGTE-V5
augmented normal basal levels of expression of autophagy
Figure 1. NFE2L2 modulates autophagy gene expression. (A) HEK293T cells were transfected with an expression vector for NFE2L2DETGE-V5.27 ChIP analysis was performed
with anti-IgG or anti-V5 antibodies and the potential AREs with the highest score were analyzed by qRT-PCR. (B) The same ChIP analysis of putative AREs in the promoter
of SQSTM1. The ﬁgures show representative data normalized as the fold of enrichment with the anti-V5 antibody vs. the IgG antibody. In (A), ACTB and an upstream region
of NQO1 that does not contain any ARE (NQO1) were analyzed as negative controls. Previously described AREs in HMOX1, NQO1, SQSTM1 and CALCOCO2 were analyzed as
positive controls. These experiments were repeated 3 times with similar results. In (B), numbers in brackets indicate the AREs from Table 1 speciﬁcally ampliﬁed. (C and D)
HEK293T and HT22 cells were submitted to sulforaphane (SFN, 15 mM) for 12 h. mRNA levels of the indicated genes were determined by qRT-PCR and normalized by Actb
levels. Data are mean § SEM (nD 3). Statistical analysis was performed with the Student t test. , p < 0.05; , p < 0.01; and , p < 0.001 vs. untreated conditions.
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genes when compared with nfe2l2-KO MEFs infected with a
control GFP-expressing lentivirus. Indeed, Sqstm1, Calcoco2,
Ulk1, Atg5, Atg7 and Gabarapl1 exhibited a robust response
(Fig. 2E).
In order to determine the impact of NFE2L2-deﬁciency in
the autophagy ﬂux, we analyzed the conversion of LC3B-I to
LC3B-II as an indicator of autophagosome formation. The
putative AREs in the LC3 coding gene could not be validated
by ChIP and we did not detect signiﬁcant changes in LC3
mRNA levels in NFE2L2-deﬁcient primary cortical neurons
(data not shown), suggesting that these changes are not con-
nected with NFE2L2 regulation of this gene. Following serum-
deprivation or rapamycin, we detected similar increases in the
levels of LC3B-II between Nfe2l2-WT and nfe2l2-KO MEFs,
indicating that NFE2L2 has little or no effect in the regulation
of autophagy by these stimuli (Fig. S1). Interestingly, H2O2
treatment during 4 h increased LC3B-II levels in both cell types,
but to a lesser extent in nfe2l2-KO MEFs (Fig. 2F and 2G). We
concluded that NFE2L2 may regulate autophagy under oxida-
tive stress conditions.
NFE2L2 deﬁciency impairs autophagy in a mouse model
of Alzheimer disease
To determine the relevance of NFE2L2 in the modulation of
autophagy, we used a mouse model of proteinopathy that
reproduces the 2 main hallmarks of AD, namely amyloidopathy
and tauopathy. These animals express mutant HsAPPV717I and
Figure 2. NFE2L2 deﬁciency results in decreased autophagy gene expression. (A) Expression levels of the indicated genes from Nfe2l2-WT and nfe2l2-KO mouse embry-
onic ﬁbroblasts (MEFs) were determined by qRT-PCR and normalized by Actb levels. Data are mean § SEM (n = 3). Statistical analysis was performed with the Student
t test. , p < 0.05; , p < 0.01; and , p < 0.001 vs. Nfe2l2-WT MEFs. (B) Representative immunoblots for the indicated proteins of Nfe2l2-WT and nfe2l2-KO MEFs.
(C) Densitometric quantiﬁcation of representative blots from (B) relative to GAPDH levels. Data are mean § SEM (n D 3). Statistical analysis was performed using the
Student t test. , p < 0.05; , p < 0.01; and , p < 0.001 vs. Nfe2l2-WT MEFs. (D) Nfe2l2-WT and nfe2l2-KO MEFs were submitted to SFN (15 mM, 6 h). mRNA levels of
the indicated genes were determined by qRT-PCR and normalized to Actb levels. (E) nfe2l2-KO MEFs were transduced with NFE2L2DETGE-V5 or GFP-expressing lentivirus
and mRNA levels of the indicated genes were analyzed by qRT-PCR following 3 and 10 after transduction. For (D) and (E), bars represent the fold of change normalized to
the untreated condition (D), or GFP-lentivirus infection (E) depicted with the dashed lines. Data are mean § SEM (n D 3). Statistical analysis was performed with the
Student t test. , p < 0.05; and , p < 0.01 vs. control conditions. (F) Nfe2l2-WT and nfe2l2-KO cells were treated with the indicated concentrations of H2O2 during 6 h.
Representative immunoblots for the indicated proteins of Nfe2l2-WT and nfe2l2-KO MEFs. (G) Densitometric quantiﬁcation of representative blots from (F) relative to
ACTB/b-actin levels. Data are mean § SEM (n D 3). Statistical analysis was performed using Student t test. , p < 0.05 vs. Nfe2l2-WT.
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HsMAPTP301L under the control of the Thy1 promoter32 and
develop intracellular HsAPP and HsMAPT aggregates after 12
mo of age. In addition, we generated HsAPP- and HsMAPT-
expressing mice in wild-type (AT-Nfe2l2-WT) and nfe2l2-
knockout (AT-nfe2l2-KO) genetic backgrounds.
First of all and to speciﬁcally determine the impact of
NFE2L2-deﬁciency in neurons, we analyzed autophagy gene
expression in hippocampal/cortical primary cultures by qRT-
PCR (Fig. 3A). As expected, nfe2l2-KO neurons exhibited
impaired expression of Sqstm1, Calcoco2, Ulk1, Atg2b, Atg5,
Atg7 and Gabarapl1. Autophagy gene expression was then
analyzed in hippocampus and brainstem (Table S5A-C) of
Nfe2l2-WT, nfe2l2-KO, AT-Nfe2l2-WT and AT-nfe2l2-KO
mice. In agreement with previous studies,33,34 11-13-mo-old
nfe2l2-KO mice had minimal changes in expression levels of
Nfe2l2-dependent genes compared to Nfe2l2-WT mice, Aox1
(aldehyde oxidase 1) being the most signiﬁcant. Comparison
of AT-Nfe2l2-WT vs. AT-nfe2l2-KO hippocampus also
showed a small yet signiﬁcant change in the expression of
Aox1, Sqstm1, Atg2b, and Gabarapl1.
Due to the small changes found in whole brain tissue, we rea-
soned that the effect of NFE2L2 on autophagy might be more
evident by looking at the neurons that express mutant HsAPP
and HsMAPT proteins. As shown in Fig. 3B-F and Fig. S3, the
Figure 3. NFE2L2 deﬁciency impairs autophagy in neurons. (A) Expression levels of the indicated genes from Nfe2l2-WT and nfe2l2-KO primary hippocampal/cortical neu-
rons were determined by qRT-PCR and normalized to Actb levels. Data are mean § SEM (n = 3). Statistical analysis was performed with the Student t test. , p <0.05 vs.
Nfe2l2-WT neurons. (B-G) Confocal analysis of double immunoﬂuorescence with anti-APP/Ab (4G8, red) and anti-SQSTM1, CALCOCO2, ULK1, ATG5, GABARAPL1 or LC3B
(green) antibodies in brain of AT-Nfe2l2-WT and AT-nfe2l2-KO. Fluorescence intensity was analyzed in the cytosol of 100 randomly chosen APP-positive neurons of each
genotype. Quantiﬁcation was derived from 3 independent experiments with 2 ﬁelds per experiment. Fluorescence intensity was quantiﬁed in 1.5-mm-thick stacks using
ImageJ software. Data are mean § SEM. Statistical analysis was performed with a Student t test. , p < 0.05; , p < 0.01; and , p < 0.001 vs. AT-Nfe2l2-WT mice.
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protein levels of SQSTM1, CALCOCO2, ULK1, ATG5 and
GABARAPL1 were reduced in neurons of the AT-nfe2l2-KO
mice expressing HsAPP, compared to those of AT-Nfe2l2-WT
mice. Similar results were obtained in HsMAPT-expressing neu-
rons (Figs. S3 and S4). LC3B was analyzed as an estimate of over-
all autophagy. We found that LC3B protein levels were also
reduced in neurons of AT-nfe2l2-KO vs. AT-Nfe2l2-WT mice
expressing HsAPP (Figs. 3G and S3) or HsMAPT (Figs. S3 and
S4). Together, these results point to the relevance of NFE2L2 in
regulation of autophagy under proteotoxic stress.
The total levels of APP protein were similar in hippocam-
pal lysates of 12-mo-old AT-Nfe2l2-WT and AT-nfe2l2-KO
mice (data not shown). Measurement of soluble and insoluble
fractions of Ab40 and Ab42 peptides by ELISA revealed simi-
lar levels of soluble peptides but reduced insoluble Ab40
(Fig. 4A) and Ab42 (Fig. 4B) in the AT-nfe2l2-KO mice.
Immunohistochemical staining of hippocampal sections for
APP/Ab (4G8 antibody) revealed more intracellular vesicles in
neurons of AT-nfe2l2-KO mice (Fig. 4D and 4E). This was
most evident in the subiculum, which is the ﬁrst brain region
to develop amyloidopathy. Taken together, these results indi-
cated that APP proteostasis was impaired in NFE2L2-deﬁcient
mice.
Regarding tauopathy, we observed no major differences
of total HsMAPT (HT7 antibody) or p-MAPT (AT8 anti-
body) in hippocampal sections of both Nfe2l2 genotypes
(Fig. 5A). However, a modest increase in the levels of both
murine endogenous MmMAPT and transgenic HsMAPT
(TAU46 antibody) and p-HsMAPT (PHF-1 antibody) pro-
teins was observed in the sarkosyl-insoluble fractions from
AT-nfe2l2-KO hippocampal homogenates (Fig. 5B-E). These
results reﬂected the fact that both transgenic and endoge-
nous MAPT tended to accumulate in the insoluble fraction
in the absence of NFE2L2.
We went on to analyze the localization of HsAPP and
HsMAPT proteins in connection to the autophagy marker
Figure 4. NFE2L2 deﬁciency leads to intracellular APP/Ab accumulation. (A-B) Determination of Ab levels by ELISA in hippocampal brain homogenates of 12–14 mo-old
AT-Nfe2l2-WT and AT-nfe2l2-KO mice. Ab40 and Ab42 levels were measured in the soluble (FS) and insoluble (FI) fractions (formic acid extracted). Soluble and insoluble
Ab40 (A) and Ab42 (B) levels were normalized by total protein amount. (C) Ratio IF:SF of Ab40 and Ab42 peptides. Data are mean § SEM (n D 10). Statistical analysis
was performed with a Student t test. , p< 0.05; and , p< 0.01 comparing AT-Nfe2l2-WT and AT-nfe2l2-KO mice. (D), Immunohistological analysis of APP/Ab expression
(4G8 antibody) in hippocampus of 13-mo-old AT-Nfe2l2-WT and AT-nfe2l2-KO mice. (E) Estimation of the number of APP/Ab-positive granules in CA1 and subiculum from
12–14-mo-old AT-Nfe2l2-WT and AT-nfe2l2-KO mice. Data are mean § SEM (n D 8). Statistical analysis was performed with the Student t test. , p<0.05; and , p < 0.01
comparing AT-Nfe2l2-WT vs. AT-nfe2l2-KO groups.
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SQSTM1 in AT-Nfe2l2-WT and AT-nfe2l2-KO mice by
double immunoﬂuorescence staining. We observed that in
AT-Nfe2l2-WT mice a large number of APP vesicles were also
decorated with the NFE2L2-regulated autophagy gene product
SQSTM1. In contrast, AT-nfe2l2-KO mice showed less coloc-
alization with SQSTM1, while APP-positive vesicles were
larger, and appeared swollen, compared to AT-Nfe2l2-WT
mice (Fig. 6A-B). HsMAPT showed a more diffuse pattern
Figure 5. NFE2L2 deﬁciency leads to accumulation of aggregated HsMAPT. (A) Immunohistochemical analysis of HsMAPT expression in hippocampus of 13-mo-old AT-
Nfe2l2-WT and AT-nfe2l2-KO mice stained with anti HT7 or AT8 antibodies that recognize total (HT7) or phosphorylated (AT8) HsMAPT. (B) Hippocampal tissue lysates
from AT-Nfe2l2-WT and AT-nfe2l2-KO mice were separated into sarkosyl-soluble (SS) and sarkosyl-insoluble (SI) fractions. Total HsMAPT and MmMAPT levels were deter-
mined using anti-TAU46 antibody that recognizes MAPT from both species. (C) Densitometric quantiﬁcation of representative blots from (B). (D) Hippocampal tissue
lysates from AT-Nfe2l2-WT and AT-nfe2l2-KO mice were separated into sarkosyl-soluble (SS) and sarkosyl-insoluble (SI) fractions and analyzed with anti-PHF1 antibody
that recognizes human p-HsMAPT. (E) Densitometric quantiﬁcation of representative blots from (D). For (C) and (E), data are mean § SEM (n D 6). Statistical analysis was
performed with the Student t test. , p < 0.05; comparing AT-Nfe2l2-WT and AT-nfe2l2-KO groups.
Figure 6. NFE2L2 modulates neuronal autophagy. (A) Confocal analysis of double immunoﬂuorescence with anti-APP/Ab (4G8, red) and anti-SQSTM1 (green) antibodies in sub-
iculum of AT-Nfe2l2-WT and AT-nfe2l2-KO. (B) Quantiﬁcation of colocalization between APP/Ab and SQSTM1 staining expressed as Mander’s coefﬁcients. (C) Confocal analysis of
double immunoﬂuorescence with anti-HsMAPT (HT7, red) and anti-SQSTM1 (green) in subiculum neurons of AT-Nfe2l2-WT and AT-nfe2l2-KO. (D) Quantiﬁcation of colocalization
between HsMAPT and SQSTM1 expressed as Mander’s coefﬁcients. For (B) and (D), Mander’s coefﬁcients were derived from 3 independent experiments with 2 ﬁelds per exper-
iment. Fluorescence was quantiﬁed in 1.5-mm-thick stacks using the JACoP plugin of ImageJ software. Data are mean § SEM. Statistical analysis was performed with a Student
t test. , p < 0.05; and , p < 0.001, comparing M1 and M2 coefﬁcients obtained from AT-Nfe2l2-WT and AT-nfe2l2-KO images.
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but once again, AT-nfe2l2-KO mice exhibited less colocaliza-
tion between HsMAPT and SQSTM1 (Fig. 6C-D).
Evidence of altered NFE2L2 activity and autophagy
in AD patients
We compared the levels of NFE2L2 and several autophagy pro-
teins in lysates from brain hippocampus of asymptomatic and
AD donors (Fig. 7A-B). The levels of NFE2L2 and one of its
downstream targets, HMOX1, were increased in AD patients
vs. controls. More importantly, the levels of the autophagy pro-
teins SQSTM1, CALCOCO2 and ATG7 were also increased.
We analyzed more speciﬁcally the NFE2L2-SQSTM1 pathway
in neurons by immunohistochemistry. It was technically not
possible to perform double labeling because of the different
retrieval requirements for each of the antigens NFE2L2,
SQSTM1 and APP, which we circumvented by analyzing 3
adjacent sections (each 4-mm thick) containing the same cells.
We observed intracellular APP/Ab in similar vesicles as
observed above in AT-Nfe2l2-WT and AT-nfe2l2-KO mice
(Fig. 7C). Interestingly, the neurons in human brain with
highest abundance of vesicular APP were localized in the ento-
rhinal cortex, and also expressed high levels of NFE2L2 and
SQSTM1 (Fig. 7C). Similarly, some scattered neurons were
found in the cortex that presented HsMAPT-positive neuroﬁ-
brillary tangles, stained with anti-HsMAPT (HT7). Such neu-
rons that intensely stained for HsMAPT were also expressing
high levels of nuclear NFE2L2 and SQSTM1 (Fig. 7C). These
results conﬁrmed in human brain that NFE2L2 was upregu-
lated in neurons suffering from proteotoxic APP/Ab or
HsMAPT insults.
Discussion
A functional connection between NFE2L2 transcriptional sig-
nature and autophagy can be predicted by the fact that both
processes participate in oxidant defense by preventing thiol
modiﬁcation or clearing oxidized proteins, respectively.35 In
search for a mechanistic connection between both processes,
we report that NFE2L2 activates the expression of some genes
involved in autophagy initiation (ULK1), cargo recognition
(SQSTM1 and CALCOCO2), autophagosome formation
Figure 7. Evidence of NFE2L2 upregulation in neurons of AD subjects expressing high levels of HsAPP and HsMAPT. (A) Immunoblot analysis of NFE2L2, HMOX1, SQSTM1,
CALCOCO2, and ATG7 in hippocampus of asymptomatic controls and patients with diagnosed AD who combined amyloidopathy and tauopathy. (B) Densitometric quanti-
ﬁcation of protein levels from representative immunoblots of (A) relative to ACTB. Data are represented as mean§ SEM (nD 5 controls and nD 5 AD subjects). Statistical
analysis was performed with a Student t test. , p < 0.05; , p < 0.01; and , p < 0.001 comparing control vs. AD groups. (C) Adjacent 4-mm-thick brain sections from
AD subjects were immunostained with anti-APP/Ab (4G8), anti-HsMAPT (HT7), anti-NFE2L2 and anti-SQSTM1 antibodies as indicated. Red arrows point to the same neu-
ron expressing HsAPP or HsMAPT, NFE2L2 and SQSTM1; blue arrows depict internal negative controls for cells that do not express HsAPP or HsMAPT and present basal
staining for NFE2L2 and SQSTM1.
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(ATG4D, ATG7 and GABARAPL1), elongation (ATG2B and
ATG5), and autolysosome clearance (ATG4D). Therefore, our
study adds NFE2L2 as a transcription factor that regulates mac-
roautophagy, next to the TFEB and FOXO family of transcrip-
tion factors.11,12 The existence of several controls for autophagy
gene expression probably assures proteostasis under different
circumstances. Thus, TFEB and FOXO3/FOXO3A participate
in multiple scenarios including rapamycin-sensitive cell signal-
ing and nutritional stress.36,37 Nonetheless, NFE2L2 may be
more relevant in tissues that support highly oxidative metabo-
lism. By this mechanism, oxidative stress-induced NFE2L2
may function under nutrient-rich conditions to upregulate
transcription of genes encoding proteins required for auto-
phagy, similar to what has been found for the transcription fac-
tors TFEB and FOXO3 under starvation conditions. As the
brain is not allowed to starve and functions largely under nutri-
ent-rich conditions when glucose is available, this may be a rel-
evant mechanism to activate autophagy in neurons.
Very few studies have performed direct ChIP sequencing for
NFE2L2, because of the low or even misleading speciﬁcity of
available antibodies.38 Therefore, we undertook a different
approach based on the analysis of other proteins that bind
ARE, MAFK and BACH1, for which more reliable ChIP
sequencing data are available in the ENCODE database. MAFK
is a leucine-zipper transcription factor that makes heterodimers
with NFE2L2.39 BACH1 is a repressor of several AREs, also
containing a leucine-zipper domain and forming heterodimers
with MAF proteins.40 Our bioinformatics analysis retrieved 25
new putative AREs located in 16 autophagy genes, many of
which were conserved in mice. We validated 11 AREs in 8 auto-
phagy genes as targets of NFE2L2 by additional ChIP analysis
in HEK293T cells and by qRT-PCR in human and mouse cells
treated with the NFE2L2 activator SFN, which disrupts the nor-
mal KEAP1-NFE2L2 interaction by making an adduct with
KEAP1 at cysteine residues.41,42 In other studies the effect of
SFN was attributed to modulation of signaling events of the
MTOR pathway through RPS6KB1/pS6K1,29 activation of
AMP kinase,30 or the MAPK/ERK pathways31 rather than to
targeting NFE2L2 itself. However, we show that the induction
of autophagy genes by SFN is impaired in nfe2l2-KO MEFs,
therefore indicating that NFE2L2 is at least partially involved.
Moreover, the expression of autophagy genes in these NFE2L2-
deﬁcient cells was increased by the re-introduction of NFE2L2
expression with the help of a lentiviral vector.
Reduced clearance of aggregation-prone proteins is a hall-
mark of many diseases, including AD, and in many a deﬁcit in
autophagy was reported.43 In agreement, impaired autophagy
of the AT-nfe2l2-KO mice correlated with altered APP process-
ing, stalled in multiple swollen vacuoles with reduced levels of
SQSTM1. Moreover, it was surprising to ﬁnd lower total levels
of Ab in AT-nfe2l2-KO compared to AT-Nfe2l2-WT. Similar
results have been reported for ATG7-deﬁcient mice, which
show impaired secretion, reduced total Ab levels and fewer
amyloid plaques.44 Several studies have found that autophago-
somes are a place for generation of Ab45-47 and BACE1/b secre-
tase and gamma secretase appear to be localized at least in part
in autophagosomes.48-50 Thus, a reduction of autophagosomes
might lead to lower Ab load. In support of this hypothesis, we
found reduced levels of autophagy markers (SQSTM1,
CALCOCO2, ULK1, AGT5, GABARAPL1 and LC3B) in the
AT-nfe2l2-KO mice (Fig. 3).
Our results are also consistent with a recent study in which
the amyloidogenic mouse model APP-PSEN1 lacking NFE2L2
exhibits enhanced accumulation of APP in multivesicular bod-
ies, endosomes, and lysosomes and shows an altered produc-
tion of amyloid proteins due to impaired autophagic ﬂux.33 In
these mice, NFE2L2-deﬁciency leads to increased amyloid pla-
que accumulation, whereas our AT-nfe2l2-KO mice exhibited a
tendency to develop fewer amyloid plaques compared to AT-
Nfe2l2-WT counterparts despite presenting with a worse cogni-
tive performance in the Morris water maze and reduced long-
term potentiation (A.I.R and A.C., to be reported elsewhere).
These ﬁndings may be reconciled considering that the APP-
PSEN1 mice exhibit a very strong amyloidogenic processing of
APP (PSEN1-driven APP processing), while our model exhibits
mild amyloidogenic processing (APP-only), suggesting a
reduced availability of extracellular Ab peptides for plaque for-
mation. In this regard, our results are consistent with those
reported in the “APP-only” transgenic mice with ATG7-deﬁ-
ciency.51 In this case, impaired autophagy inﬂuences unconven-
tional secretion of Ab to the extracellular space and thereby
affects Ab plaque formation. All in all, available data comply
with the hypothesis that autophagic elimination of APP is cru-
cial to prevent amyloidopathy and suggest a role of NFE2L2 in
APP clearance.
Although HsMAPT can be degraded through several pro-
teolytic pathways, it is increasingly recognized that impaired
autophagy also plays a central role in tauopathy.52 Thus,
MTOR signaling regulates HsMAPT phosphorylation and
autophagic degradation,53 whereas inhibition of MTOR with
rapamycin has the opposite effect.54,55 Our results are fully con-
sistent with at least partial NFE2L2-dependent autophagic deg-
radation of HsMAPT, given its colocalization with SQSTM1 in
autophagic vacuoles. Our observations also ﬁt with a previous
report indicating that HsMAPT is a cargo of CALCOCO2 to be
delivered to the lysosome in autophagosomes and that deﬁ-
ciency in this protein aggravates tauopathy in mice.18
It is not fully clear yet if the NFE2L2 signature is altered in
the degenerative or even in the aging brain. In agreement with
a previous report,33 we found minimal changes of ARE-gene
expression between 11-13-mo-old Nfe2l2-WT and nfe2l2-KO
mice. Also, as reported for the APP-PSEN1 mice,33 our results
show modest or no changes in autophagy genes in the hippo-
campus and brainstem of AT-nfe2l2-KO vs. AT-Nfe2l2-WT
mice when the whole brain parenchyma is analyzed. Therefore,
the strong evidence for a role of NFE2L2 in autophagy genes
gathered in cell culture was not reﬂected in vivo when we ana-
lyzed the whole brain parenchyma. However, in double-immu-
noﬂuorescence assays, we did ﬁnd differences in the levels of
autophagy proteins when we compared HsAPP-HsMAPT-
expressing neurons from AT-Nfe2l2-WT vs the AT-nfe2l2-KO
brains. Therefore, the effect of NFE2L2 was detected speciﬁcally
in the neurons that are under proteotoxic attack, and probably
for this reason could ﬁnd a role that was not be detected in the
whole brain since most cells are not expressing HsAPP or
HsMAPT.
Regarding AD patients, while there is overwhelming evi-
dence of impaired autophagy,56-59 the role of NFE2L2 is
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controversial. A highly cited study showed that NFE2L2 is pre-
dominantly localized in the cytoplasm of AD hippocampal neu-
rons, suggesting reduced NFE2L2 transcriptional activity in the
brain.60 However, other studies have reported increased ARE-
regulated proteins in AD brains, such as HMOX1, NQO1, or
SQSTM1.61-64 Our results, both with protein lysates of hippo-
campus and with immunohistochemistry are in line with these
latter reports, because we found increased nuclear NFE2L2
expression in proteinopathic neurons. One possible explanation
for this discrepancy is that NFE2L2 levels might change during
disease progression and in different brain regions. It is interest-
ing to add that the rodent Octodon degus naturally develops
with aging proteinopathic hallmarks of AD that correlate with
increased Nfe2l2 mRNA levels,65 further suggesting upregula-
tion of NFE2L2 to combat proteinopathy.
Our work supports the observation that phosphorylated
SQSTM1 is increased in AD samples.64 This modiﬁed form of
SQSTM1 has high binding afﬁnity to KEAP1 and drives this
NFE2L2 repressor to autophagosomes.16 It is then plausible to
think that SQSTM1-mediated removal of KEAP1 would result
in NFE2L2 accumulation, which in turn would also induce
expression of SQSTM1 as well as other autophagy genes provid-
ing a feed-forward loop.
A corollary of our study is that NFE2L2 might be a therapeutic
target for proteinopathies such as AD. On the one hand, we
found that NFE2L2-deﬁciency impairs autophagy in AT-nfe2l2-
KO mice (Figs. 3, S3 and S4). We interpret these data as a need of
NFE2L2 for optimal autophagy response to proteinopathy. On
the other hand, in AD patients, NFE2L2 and at least HMOX1,
SQSTM1, CALCOCO2 and ATG7 are upregulated in the hippo-
campus as determined by immunoblot (Fig. 7A-B), and NFE2L2
and SQSTM1 proteins are increased in HsAPP- and HsMAPT-
injured neurons as determined by immunohistochemistry
(Fig. 7C). Thus, it follows that the diseased brain is upregulating
NFE2L2 in an attempt to maintain proteostasis. In fact, the still
living proteinopathic neurons that we can see by immunohisto-
chemsitry in the postmortem samples exhibit increased levels of
NFE2L2 and SQSTM1, suggesting that they may better suited to
sustain proteotoxicity. This is just a correlation since we cannot
compare with the neurons that have already disappeared, but
altogether, our rationale suggests that NFE2L2 activates an auto-
phagy defensive program to maintain proteostasis.
However, in order to consider NFE2L2 as a therapeutic tar-
get to combat proteinopathies, the key question is whether it
will be useful to increase NFE2L2 levels beyond the physiologi-
cal response. In other words, is the physiological NFE2L2
response to proteinopathy at saturating levels and would supra-
physiological upregulation of NFE2L2 have beneﬁcial or delete-
rious effects? A partial answer to these questions may be
provided by the analysis of epidemiological data, which indicate
that the NFE2L2 gene is highly polymorphic and some single
nucleotide polymorphisms found in its promoter regulatory
region may provide a range of “physiological” variability in
gene expression at the population level. For instance, Von Otter
et allink 66 found that one haplotype allele of the NFE2L2 pro-
moter was associated with 2 y earlier age at AD onset. These
results are also consistent in other neurodegenerative proteino-
pathies. Thus, Von Otter et al performed a meta-analysis of
NFE2L2 haplotypes and found association of the haplotype of
the fully functional promoter with decreased risk and delayed
onset of Parkinson disease.67 Observations along the same lines
have been made in amyotrophic lateral sclerosis.68 Given the
population variability in NFE2L2 expression it is conceivable
that a small pharmacological upregulation of NFE2L2, compa-
rable to the maximal physiological response found at the popu-
lation level, will indeed reinforce proteostasis. In this regard,
several preclinical studies have so far attempted to upregulate
NFE2L2 in an effort to mitigate neurodegenerative disease-
associated phenotypes. For instance, the life expectancy of
transgenic mice expressing human mutant SNCAA53T is largely
increased when crossed with mice overexpressing NFE2L2 in
astrocytes69 and the NFE2L2 activator dimethyl fumarate,
already in clinical use for multiple sclerosis, reduces SNCA tox-
icity.70 Other NFE2L2 activators are being studied for allevia-
tion of proteinopathies such as spinal and bulbar muscular
atrophy.71 Future work will be needed to determine if pharma-
cological induction of NFE2L2 may be a valid strategy to facili-
tate degradation of toxic proteins in the brain.
Material and methods
Bioinformatics analysis
Putative AREs in 26 autophagy-related gene promoters were
identiﬁed in The Encyclopedia of DNA Elements at UCSC
(ENCODE)25 for the human genome (Feb. 2009) taking as ref-
erence the available information from chromatin immunopre-
cipitation (ChIP) of ARE binding factors MAFK and BACH1.
The putative MAFK and BACH1 binding regions were localized
in 200- to 400-base pair-long DNase-sensitive and H3K27Ac-
rich regions, i.e., most likely regulatory promoter regions. In
addition, a frequency matrix of the consensus ARE sequence
based on the JASPAR database26 was converted to a position-
speciﬁc scoring matrix (PSSM) (Table S1) by turning the fre-
quencies into scores through the log2(odd-ratio) (odd ratio:
observed frequency/expected frequency). One unit was added
to each frequency to avoid log(0). Then a script was generated
with the Python 3.4 program (Table S2) to scan the promoter
sequences with candidate AREs retrieved from ENCODE with
the PSSM. The max score was calculated by adding the indepen-
dent scores for each of the 11 base pairs of the consensus ARE
sequence with the PSSM. The relative score (scorerelative) was
calculated from this max score (score of the sequencemax) as:
scorerelative D (score of the sequencemax – scoremin possible)/
(scoremax possible – scoremin possible). The min possible score
(scoremin possible) is calculated as the lowest possible number
obtained for a sequence from the PSSM and the max possible
score (scoremax possible) is the highest possible score that can be
obtained. We considered putative ARE sequences those with a
scorerelative over 80%, which is a commonly used threshold for
the computational framework for transcription factor binding
site/TFBS analyses using PSSM. The conservation of the
NFE2L2 putative binding sequences in mice was analyzed by
comparing the mouse genome through 2 different methods
from the UCSC Genome Browser: BLAT search genome useful
for high conservation and Comparative Genomics searching
conservation in the mouse genome using Multiz Align (multiz
100way) (Tables S1, S2 and S3).
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Cell culture and reagents
Mouse embryonic ﬁbroblasts (MEFs), mouse hippocampus-
derived HT22 cells and human embryonic kidney HEK293T
cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(Sigma-Aldrich, D5648) supplemented with 10% fetal bovine
serum (HyClone, CH30160.03) and 80 mg/ml gentamicin (Lab-
oratorios Normon, 763011.1). Hippocampal/cortical neurons
were obtained from E17-E18 mouse embryos. Brieﬂy, embry-
onic hippocampi were incubated in 0.25% trypsin (Gibco Life
Technologies, 12604–013) plus 1 mg/ml DNAse-I (Roche,
10104159001) at 37C for 20 min. After mechanical dissocia-
tion and centrifugation (900 £ g, 5 min) cells were plated in
minimum essential medium (Gibco Life Technologies, 17504–
044) supplemented with 20% glucose (Sigma-Aldrich, 16301),
5% horse serum (Gibco Life Technologies, 26050–088), 5% fetal
bovine serum and 80 mg/ml gentamicin, and incubated for
24 h. After plating, the medium was changed to phenol red-free
neurobasal medium (Gibco Life Technologies, 10888–022) sup-
plemented with B27 (Gibco Life Technologies, 17504–044) and
the neurons were maintained under these conditions for
10 days in vitro. R,S-sulforaphane (SFN; LKT Laboratories,
Inc., S8044).
Production of lentiviral stocks and infection of nfe2l2-KO
MEFs
Recombinant lentiviral stocks were produced in HEK 293T/17
cells by cotransfecting 10 mg of transfer vector (GFP or
NFE2L2DEGTE-V5), 6 mg of envelope plasmid pMD2.G (Addg-
ene, 12259; deposited by Dr. Didier Trono) and 6 mg of packag-
ing plasmid pSPAX2 (Addgene, 12260; deposited by Dr. Didier
Trono), using Lipofectamine 2000 Reagent (Invitrogen Life
Technologies, 116668–019). After 12 h at 37C the medium
was replaced with fresh Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum and virus particles were har-
vested at 24 h and 48 h post-transfection. The nfe2l2-KO MEFs
were incubated with the lentivirus for 24 h, and mRNA was
extracted 3 and 10 d after lentiviral transduction.
Chromatin immunoprecipitation (ChIP) assay
HEK293T cells were grown on 10-cm plates until they reached
85% conﬂuence and transfected with an NFE2L2 expression
plasmid that lacks the high-afﬁnity binding site for KEAP1
and contains a V5 tag (NFE2L2DETGE-V5).27 Brieﬂy, cells were
crosslinked with 1% formaldehyde (Fluka, 47630) and the
reaction was stopped with 125 mM glycine (Bio-Rad, 161–
0718). Cells were then washed twice with cold phosphate-
buffer (10 mM PO4
3-, pH 7,4, 137 mM NaCl, 2.7 mM KCl),
lysed and sonicated in order to obtain adequate fragment sizes
of DNA. Supernatant was diluted 10-fold with ChIP dilution
buffer (0.01% sodium dodecyl sulfate [Sigma-Aldrich, 71725],
1.1% Triton X-100 [Sigma-Aldrich, T8787], 1.2 mM ethylene-
diaminetetraacetic acid, 16.7 mM Tris-HCl, pH 8.1, 167 mM
NaCl, 1 mM phenylmethylsulfonyl ﬂuoride [Sigma-Aldrich,
P7626], 1 mg/ml leupeptin [Sigma-Aldrich, L8511]) and pre-
cleared with protein G Sepharose (GE Healthcare, 17-0618-
01). ChIP was carried out with anti-V5 antibody (Life
Technologies, 37–7500) or anti-IgG (Abcam, ab18413). DNA
was eluted and puriﬁed, analyzing the presence of previously
identiﬁed putative AREs by quantitative real-time polymerase
chain reaction (qRT-PCR) with speciﬁc primers (Table S4).
Samples from at least 3 independent immunoprecipitations
were analyzed.
Transgenic mice
Animals were housed at room temperature under a 12-h light-
dark cycle. Food and water were provided ad libitum and mice
were cared for according to a protocol approved by the Ethical
Committee for Research of the Universidad Autonoma de
Madrid following institutional, Spanish and European guide-
lines (Boletın Oﬁcial del Estado of 18 March 1988; and 86/609/
EEC, 2003/65/EC European Council Directives). HsAPP
V717I
mice expressing in heterozygosis the HsAPP695 isoform with
the V717I mutation under the control of the Thy1 promoter,
were backcrossed with C57/BL6j-Nfe2l2C/C or C57/BL6j-
nfe2l2¡/¡ mice for over 5 generations. Similarly, HsMAPTP301L
mice, expressing in homozygosis the longest isoform of
HsMAPT with the P301L mutation (Tau.4R/2N-P301L) under
control of the mouse Thy1 gene promoter, were crossed with
C57/BL6j-Nfe2l2C/C or C57/BL6j-nfe2l2¡/¡ for over 5 genera-
tions. HsAPP-HsMAPT-Nfe2l2C/C (AT-Nfe2l2-WT) and
HsAPP-HsMAPT-nfe2l2¡/¡ (AT-nfe2l2-KO) mice were
obtained by crossing the proper founder mice from above.
Genotypic characterization of the AT-Nfe2l2-WT transgenic
mice was described previously.32,72,73 Animals were anesthe-
tized with 8 mg/kg ketamine and 1.2 mg/kg xylazine and per-
fused with phosphate-buffered saline. The brains were
sectioned along the sagittal axis and the right hemispheres were
post-ﬁxed in 4% paraformaldehyde during 16 h and cryopro-
tected by soaking in 30% sucrose solution in phosphate buffer
until they sank. The left hemispheres were rapidly dissected
and frozen for biochemical analysis.
Human patients
All procedures were approved by the ethics committee of the
Tissue Bank of Fundacion CIEN (Madrid, Spain). Frozen
post-mortem brain tissues were obtained from 5 control sub-
jects (age range 59–78 y) and 5 patients with Alzheimer dis-
ease (age range 73–94 y) within a 5-h post-mortem interval,
according to the standardized procedures of the Tissue Bank
of Fundacion CIEN. Information on patient samples, includ-
ing APOE genotype, is provided in Table S6. The brain sam-
ples used in this study belong to patients with a clinical
history that indicates lack of familial cases of AD. The control
subjects had no background of neuropsychiatric disease and a
full neuropathological examination excluded relevant brain
pathology. Alzheimer disease diagnosis was conﬁrmed by
HT100 staining of frozen tissue sections from the same cases
used in the immunoﬂuorescence studies.
Immunohistochemistry of human tissue
Four-mm-thick parafﬁn-ﬁxed consecutive brain sections were
immunostained as described previously.74 The primary
1912 M. PAJARES ET AL.
antibodies and optimal dilutions are summarized in Table S7.
For NFE2L2 immunostaining, brain sections were stained with
Histostain-bulk-SP IHC kit broad spectrum (Thermo Fisher
Scientiﬁc, 959943B) using primary anti-NFE2L2 antibody
(Thermo Fisher Scientiﬁc, PA13831; 1:200). A negative control
omitting primary anti-NFE2L2 antibody yielded no signal
(data not shown).
HsMAPT tissue extraction
Mouse brain tissues were homogenized in 0.2 ml of ice-cold
buffer (0.1 M 3-[N-morpholino]propanesulfonic acid, pH 7.0,
1 mM ethylenediaminetetraacetic acid, 0.5 mM MgSO4, 1 M
sucrose [Panreac AppliChem, A2211]) containing 1 mM NaF,
1 mM Na3VO4, 1 mM phenylmethylsulfonyl ﬂuoride and
10 mg/ml each of aprotinin (Sigma-Aldrich, A1153) and 1 mg/
ml leupeptin (Sigma-Aldrich, L8511). The homogenates were
cleared by centrifugation at 50,000 £ g for 20 min at 4C, and
the supernatants were collected as soluble fractions. To prepare
the sarkosyl-insoluble fraction, the pellets were resuspended in
lysis buffer (0.1 M 3-[N-morpholino]propanesulfonic acid, pH
7.0, 10% sucrose, 2 mM ethylene glycol tetraacetic acid [Sigma-
Aldrich, E3889], 0.5 mM MgSO4, 500 mM NaCl, 1 mM MgCl2,
10 mM NaH2PO4, 20 mM NaF) containing 1% N-lauroylsarco-
sine (sarkosyl; Sigma-Aldrich, L9150) with protease inhibitors
(Sigma-Aldrich, L8511, A1153 and P7626), vortexed for 1 min
at room temperature, incubated at 4C for 16 h, and then cen-
trifuged at 200,000 £ g for 30 min at room temperature. The
supernatant fractions were collected as sarkosyl-soluble frac-
tions, and the pellets, sarkosyl-insoluble fractions, were resus-
pended in sodium dodecyl sulfate protein loading buffer and
incubated at 95C for 5 min.
Immunoblotting
Immunoblots were performed as described previously.75 The
primary antibodies used are presented in Table S7. Mem-
branes were analyzed using the appropriate peroxidase-con-
jugated secondary antibodies (anti-mouse and anti-rabbit
from GE Healthcare UK Limited, NA931V and NA934V,
and anti-goat from Santa Cruz Biotech, sc-2020). Proteins
were detected by enhanced chemiluminescence (GE Health-
care, RPN2232).
Immunohistochemistry and immunoﬂuorescence
of mouse tissues
Sagittal series of 30-mm-thick sections were obtained in a freez-
ing microtome and stained as indicated previously.76 The pri-
mary antibodies used are described in Table S7. Antigen
retrieval for APP and Ab detection was performed by incubat-
ing the sections for 5 min in formic acid.
Analysis of mRNA levels
Total RNA extraction, reverse transcription and quantitative
PCR were done as detailed elsewhere.76 Primer sequences are
shown in Tables S8 and S9. To ensure that equal amounts of
cDNA were added to the PCR, the housekeeping gene ACTB
was ampliﬁed. Data analysis was based on the DDCT method
with normalization of the raw data to housekeeping genes. All
PCRs were performed in triplicate.
Ab determination by ELISA
Ab measurements were performed using 2 ELISA kits, one for
each fragment (Ab1–40 and Ab1–42) (Novex, Thermo Fisher
Scientiﬁc, KHB3481 and KHB3441, respectively) following the
manufacturer’s instructions. The samples were sonicated (5 sec)
in 10 vol of protein lysis buffer (20 mM [4-{2-hydroxyethyl}-1-
piperazineethanesulfonic acid] pH 7.9, 100 mM NaCl, 1 mM
ethylene glycol tetraacetic acid, 1 mM ethylenediaminetetraace-
tic acid, 1% Triton X-100, 5 mM dithiothreitol, 2.5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, and complete
protease inhibitor cocktail). The lysate was centrifuged (18,000
£ g, for 10 min at 4C). The supernatant fraction was consid-
ered soluble and the pellet fractions were further extracted in
formic acid by sonication, and centrifuged. Results were
expressed as pg/mg of protein measured by the BCA method
(Thermo Fisher Scientiﬁc, 23225 )] using BSA as standard.
Image analysis and statistics
Different band intensities corresponding to immunoblot detec-
tion of protein samples were quantiﬁed using MCID software
(MCID, Cambridge, UK). Fluorescence intensity and M1 and
M2 colocalization coefﬁcients were measured by Mander’s
analysis using the ImageJ JACoP plug-in. Student t test was
used to assess differences between groups. P<0.05 was consid-
ered signiﬁcant. Unless otherwise indicated, all experiments
were performed at least 3 times and all data presented in the
graphs are the mean of at least 3 independent samples. Results
are expressed as mean § SEM.
Abbreviations
ACTB actin b
AD Alzheimer disease
Aox1 aldehyde oxidase 1
APP amyloid b precursor protein
ARE antioxidant response element
ATG5 autophagy-related 5
AT-nfe2l2-KO transgenic mice expressing HsAPPV717I
and HsMAPTP301L in an nfe2l2-knokc-
out genetic background
AT-Nfe2l2-WT transgenic mice expressing HsAPPV717I
and HsMAPTP301L in a wild-type
genetic background
Ab amyloid-b peptide
BACH1 BTB domain and CNC homolog 1
CALCOCO2/NDP52 calcium binding and coiled-coil
domain 2
ChIP chromatin immunoprecipitation
ENCODE encyclopedia of DNA elements at the
University of California, Santa Cruz
FI formic acid extracted insoluble fraction
FOXO forkhead box O
AUTOPHAGY 1913
FS formic acid-extracted soluble fraction
GABARAPL1 GABA type A receptor associated pro-
tein like 1
GAPDH glyceraldehyde-3-phosphate
dehydrogenase
GFP green ﬂuorescent protein
HsMAPT/TAU human microtubule associated protein
tau
HMOX1 heme oxygenase 1
JASPAR transcription factor binding proﬁle
database
KEAP1 kelch like ECH associated protein 1
MAFK MAF bZIP transcription factor K
MAP1LC3/LC3B microtubule associated protein 1 light
chain 3
MEFs mouse embryo ﬁbroblasts
MTOR mechanistic target of rapamycin (ser-
ine/threonine kinase)
NQO1 NAD(P)H quinone dehydrogenase 1
NFE2L2 nuclear factor, erythroid 2 like 2
nfe2l2-KO nfe2l2-knockout mice
Nfe2l2-WT wild-type mice
PSSM position-speciﬁc scoring matrix
qRT-PCR quantitative real-time polymerase chain
reaction
SFN sulforaphane
SQSTM1/p62 sequestosome 1
TFEB transcription factor EB
ULK1 unc-51 like autophagy activating kinase 1
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